Patent
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells (US Patent 12122850)
LamKap Bio gamma AG · Granted Oct 22, 2024 · Filed Mar 14, 2023
Patent number: 12122850 Kind code: B2 Granted: 2024-10-22 Filed: 2023-03-14 Inventors: Eric Hatterer (Valleiry, FR); Anja Seckinger (Lachen, CH); Dirk Hose (Pfaeffikon, CH) Assignees: LamKap Bio gamma AG (Pfaeffikon Sz, CH) CPC: A61P 35/00; C07K 16/3007; C07K 16/464; C07K 16/468; C07K 2317/31; C07K 2317/565; C07K 2317/71
Abstract
The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination
Showing a preview — retrieve the full document via the Exa API.
Powered by the Exa API